Ken Mulvany

(Contributor)

I’m a healthcare and technology entrepreneur and investor. I lead BenevolentAI, a £bn valuation British technology company I founded in 2013 which applies AI to accelerate scientific discovery. Previously I founded Proximagen, a UK biotech focussed on central nervous system disorders. It was sold to a US pharmaceutical company in 2012 for $555m. I sit on the advisory panel for the UK Government on Artificial Intelligence and I am a member of the All Party Artificial Intelligence Parliamentary Group.